Letrozole, Aromatase inhibitor

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

Cytochrome P450 3A4 commonly referred to as CYP3A4 is an important enzyme within the cytochrome P450 family. It catalyzes the oxidation of small organic molecules in the liver affecting drug metabolism. CYP3A4 has a molecular weight of about 57 kDa and expresses primarily in the liver and intestines. Aromatase also known as CYP19A1 plays an important role in estrogen biosynthesis by converting androgens to estrogens. Meanwhile CYP11B1 and CYP11B2 are involved in corticosteroid biosynthesis pathways with expression in the adrenal cortex.

Biological function summary

Enzymes like CYP3A4 and aromatase significantly impact steroid metabolism and drug clearance in humans. Aromatase is part of the aromatase complex which includes NADPH-cytochrome P450 reductase facilitating its function in hormone synthesis. CYP11B1 and CYP11B2 participate in corticoid and mineralocorticoid production influencing various physiological processes. These enzymes regulate hormone levels ensuring homeostasis and influencing responses to pharmacological treatments such as those involving aromatase inhibitors.

Pathways

Enzymes like CYP3A4 are vital in the cytochrome P450-mediated drug metabolism pathway and participate in the steroid hormone biosynthesis pathway. Aromatase connects to estrogen biosynthesis interacting with proteins such as CYP17A1 further linking to the biosynthesis of sex steroids. Both cytochrome P450 pathways and steroid hormone biosynthesis pathways contribute to physiological homeostasis and drug efficacy interacting with compounds like letrozole a well-known aromatase inhibitor.

CYP3A4 and related enzymes like aromatase have implications in drug interactions and hormone-related cancers such as breast cancer. Aromatase inhibitors including letrozole are important in treating hormone-receptor-positive breast cancer by reducing estrogen levels. Disorders related to corticosteroid biosynthesis involve CYP11B1 and CYP11B2 with links to conditions like congenital adrenal hyperplasia and hypertension. The enzyme interactions involved such as those between aromatase and its inhibitors highlight the therapeutic potential in managing hormone-dependent conditions.